SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 biochip.
Certified and licensed to undertake clinical trials in China, Zhongshan TopGene is a wholly-owned subsidiary of TopGene Tech (Guangzhou) Co which specialises in the diagnosis and treatment of cancer in the country.
These LDTs involve liquid biopsy, which is a cheaper, faster and simpler alternative to an invasive tissue biopsy, that enables doctors and patients to discover a range of information about a tumour through a simple blood sample.
Including the latest partnership, Biolidics has a total of four partnerships with established medical and clinical laboratories and medical technology companies for the development and commercialisation of LDTs in China.
Shares in Biolidics closed 0.5 cent lower at 28 cents.
